Cefcanel daloxate
Alternative Names: KY 109Latest Information Update: 07 Apr 1999
At a glance
- Originator Kyoto Pharmaceutical Industries
- Developer AstraZeneca
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Otitis media; Respiratory tract infections
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 04 Jun 1998 Discontinued-III for Otitis media in Sweden (PO)
- 04 Jun 1998 Discontinued-III for Respiratory tract infections in Sweden (PO)